Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma

NCT01765231 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT01765231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01765231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma
Lead sponsor
Peking University
Phase
Phase 4
Overall status
Unknown status
Start date
January 31, 2013
Completion date
December 31, 2017
Enrollment
190 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b